00:00Eli Lilly said its experimental daily obesity pill helped patients maintain most of their weight loss after switching from injectable drugs like ZepBound and Novo Nordisk's WegoV in a late stage trial.
00:12The company has now filed the pill for FDA approval with a priority review that could speed a decision, sending Lilly shares up more than 2% on the news.
00:21Patients who transitioned from WegoV maintained about 95% of their weight loss, while those switching from ZepBound kept roughly 80%, highlighting the pill's potential as a needle-free maintenance option.
00:33While Novo Nordisk may bring an oral obesity drug to market first, analysts say Eli Lilly's results position it to capture significant share in the booming GLP-1 market if pricing and coverage align.
Comments